Safety narratives are the clearest case in regulated writing where volume and judgement pull in opposite directions. A narrative is a structured account assembled from data that already exists in the case record — and there can be thousands of them, each needing to be complete, internally consistent, and consistent with the case data.
That combination is why narratives get written late, by whoever is available, under deadline. And it is why they are a legitimate target for automation, provided one line is held.
This is how we approach safety narratives.
The line: description versus assessment
A narrative contains two kinds of content and they should be treated completely differently.
The description is the sequence of events: patient characteristics, medical history, concomitant medications, the event, its timing relative to drug administration, actions taken, outcome. All of it exists in the case record. Writing it out is transcription with structure, and it is where the hours go.
The assessment is causality, expectedness, and the clinical reasoning in a company comment. That is a medical judgement made by a qualified person who signs it.
A system that drafts the description and leaves the assessment is doing the right thing. One that proposes a causality assessment has crossed into a different risk category, and should be classified and validated accordingly rather than described as narrative automation.
Consistency with the case record is the requirement
The failure that matters is a narrative stating something the case record does not support — a date that does not match, a concomitant medication that was not recorded, an outcome stated more definitively than the data allows.
These are not stylistic problems. A narrative inconsistent with its case is a data integrity issue, and at the volumes involved it is not realistically caught by sampling.
So the design requirement is that each statement is traceable to the field it came from, and that a reviewer can confirm it without leaving the document. safety narratives is built around that, and clinical documentation is the underlying property. The practical effect is that review becomes checking rather than reading for plausibility — which matters because plausibility is precisely what a fluent wrong statement has.
Review at volume, honestly
This is where narrative automation either works or quietly becomes a rubber stamp, and it deserves a straight answer rather than a reassuring one.
If a reviewer must approve several hundred narratives a shift, review is nominal. Everyone involved knows it, and claiming human oversight that cannot physically occur is worse than acknowledging the automation, because it misrepresents the control to the people relying on it.
The workable approaches are to make per-narrative review genuinely fast — which requires source traceability, so verification is a glance rather than an investigation — and to tier review by case characteristics, with full review for serious, fatal and unexpected cases and lighter review for the high-volume routine tail. That tiering is a risk-based decision that should be documented and justified, not an operational drift. why human-in-the-loop can't be a footnote covers why the rejection path matters as much as the review itself.
Aggregate consistency, which humans cannot do
An underrated benefit. Individual narratives can each be correct and the set can still be inconsistent — the same event described differently across cases, the same medication coded two ways, terminology drifting across a reporting period as different writers contributed.
A reviewer reading one narrative cannot see this. It is visible only across the set, and it is the kind of thing that surfaces in an inspection as evidence of uncontrolled process.
Checking consistency across a population of narratives is mechanical work that benefits from automation more clearly than first-draft generation does, and it is rarely what gets demonstrated.
What the regulators expect
There is no narrative-specific AI guidance. What applies is the general expectation that a system producing regulated records is fit for intended use, plus the AI-specific assurance direction.
For a narrative system that means: a stated intended use with the assessment fields explicitly excluded, acceptance criteria defined before evaluation, an evaluation set that gates releases, a specific test for statements unsupported by the case record rather than only an aggregate quality score, a named human review role at a defined gate, drift monitoring, and a fallback.
That fallback is specific in a safety context. Reporting obligations do not pause because a system is unavailable, so the manual path has to work and should be exercised before go-live rather than assumed. AI validation services is the practice and pharmacovigilance the wider process.
Where to start
The routine, non-serious tail first. Highest volume, lowest judgement, and the place where backlog actually accumulates. Keep serious, fatal and unexpected cases on the existing path while the approach is established.
Then aggregate consistency checking across the set. Leave causality assessment where it is.
TraceDraft is the product, safety narratives the practice, and book a demo to see it against your own cases.
Where to go next
Explore GxP Copilot for AI-native validation, TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.
